American Portfolios Advisors Ultragenyx Pharmaceutical Inc. Transaction History

American Portfolios Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Mar 20, 2023	BUY	$45.8 - $85.4 $3,709 - $6,917	81 New	81 $4.83 Million
Q1 2022 Mar 21, 2023	BUY	$62.2 - $84.4 $6,779 - $9,199	109 New	109 $7.92 Million
Q4 2021 Mar 21, 2023	BUY	$73.71 - $87.86 $7,149 - $8,522	97 New	97 $8.16 Million
Q3 2021 Mar 22, 2023	BUY	$77.92 - $102.4 $5,999 - $7,884	77 New	77 $6.95 Million
Q2 2021 Mar 22, 2023	BUY	$92.19 - $115.71 $6,453 - $8,099	70 New	70 $6.68 Million
Q1 2021 Mar 22, 2023	BUY	$106.9 - $167.73 $7,055 - $11,070	66 New	66 $7.52 Million
Q4 2020 Mar 22, 2023	BUY	$84.4 - $177.39 $2,869 - $6,031	34 New	34 $4.71 Million
Q3 2020 Mar 22, 2023	BUY	$72.98 - $90.0 $2,262 - $2,790	31 New	31 $2.55 Million
Q3 2019 Mar 24, 2023	BUY	$42.5 - $63.11 $382 - $567	9 Added 1.94%	472 $20.2 Million
Q2 2019 Mar 24, 2023	BUY	$54.93 - $74.36 $25,432 - $34,428	463 New	463 $29.4 Million
Q1 2019 Mar 24, 2023	SELL	$39.87 - $69.36 $637 - $1,109	-16 Reduced 3.42%	452 $31.4 Million
Q4 2018 Mar 24, 2023	BUY	$38.89 - $77.3 $18,200 - $36,176	468 New	468 $20.3 Million

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

Stay updated on American Portfolios Advisors with notifications on news.